Sanofi Collaborates with Orano Med for the Development of Next-Generation Radioligand Therapies
Shots:
- Sanofi and Orano Med have signed an agreement to employ their expertise for the development of next-generation radioligand therapies targeting rare cancers
- Both the companies will invest in a new entity that will function under the Orano Med brand for the discovery, design & clinical development of next-generation lead-212 isotopes based radioligand therapies (RLTs), strengthening Orano Med's pipeline and capabilities
- As per the agreement, Sanofi will invest ~$325.83M (€300M) in equity, a 16% equity stake in the new entity valued at ~$2.06B (€1.9B)
Ref: Sanofi | Image: Sanofi and Orano Med
Related News: Sanofi’s Enjaymo (sutimlimab) Receives EC’s Approval for Hemolytic Anemia in Adult Patients with Cold Agglutinin Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
